ReviewAmerican journal of cancer research2020
Management of nephrotoxicity of chemotherapy and targeted agents: 2020.
Review in American journal of cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 45 citations in OpenAlex.
- Head and neck squamous cell carcinoma: current and emerging therapeutic strategies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Mechanistic Insights intoInternational journal of molecular sciences · 2026Article
- Bipolar disorder in oncology: Considerations for the psychiatrist.Journal of mood and anxiety disorders · 2026Review
- The Therapeutic Potential of Stem Cell Therapy for Doxorubicin-Induced Cardiotoxicity: A Narrative Review.Health science reports · 2026Article
- Kidney disease and transplantation in childhood cancer survivors.Pediatric nephrology (Berlin, Germany) · 2026Review
- Evaluation of the effects of diosmin in cyclophosphamide-induced nephrotoxicity: an experimental animal study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Omega-3 fatty acids and chemotherapy-induced toxicities: mechanisms and emerging evidence with a pediatric focus.Nutrition & metabolism · 2025Review
- B-Mode Ultrasound May Be an Early Marker in Acute Kidney Injury.Diagnostics (Basel, Switzerland) · 2025Article
- Early Acute Kidney Injury and Its Association With Survival in Patients With Metastatic Non-Small-Cell Lung Cancer Treated With Front-Line Immunotherapy-Based Therapies.Cancer medicine · 2025Article
- Carcinogenesis Associated with Toxin Nephropathy: Proposed Mediation by Phosphate Toxicity.Cells · 2025Review
- Platinum-based chemotherapies-induced nephrotoxicity: mechanisms, potential treatments, and management.International urology and nephrology · 2025Review
- Designing novel cabozantinib analogues as p-glycoprotein inhibitors to target cancer cell resistance using molecular docking study, ADMET screening, bioisosteric approach, and molecular dynamics simulations.Frontiers in chemistry · 2025Article
- Targeted Modulation of Mitochondrial Oxidative Stress Ameliorates 5-Fluorouracil-Induced Renal Injury in BALB/c Mice.Oxidative medicine and cellular longevity · 2025Article
- A low-dose pemetrexed-cisplatin combination regimen induces significant nephrotoxicity in mice.BMC nephrology · 2024Article
- Article
- Pan-cancer analyses of the associations between 109 pre-existing conditions and cancer treatment patterns across 19 adult cancers.Scientific reports · 2024Article
- Review
- Curcumin supplementation prevents cisplatin-induced nephrotoxicity: a randomized, double-blinded, and placebo-controlled trial.Research in pharmaceutical sciences · 2023Article
- Redox Regulation of Nrf2 in Cisplatin-Induced Kidney Injury.Antioxidants (Basel, Switzerland) · 2023Review
- Thymoquinone Ameliorates Carfilzomib-Induced Renal Impairment by Modulating Oxidative Stress Markers, Inflammatory/Apoptotic Mediators, and Augmenting Nrf2 in Rats.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nephrotoxic effects of certain chemotherapeutic agents such as cisplatin and ifosfamide has been well documented and these effects are carefully managed by oncologists during their usage. The introduction of targeted agents has added a new challenge to cancer management as their nephrotoxic effects and associated management is in the process of being adopted by oncologists. This work is a compilation of side effects on the renal system due to various chemotherapeutic, immunotherapeutic and targeted agents followed by their recommended management.
Indexed as
Identifiers
33414992PMC7783750W3086881773What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.